About Careers Internship MedBlog Contact us

US Chapter of 'Advinus Therapeutics' Inaugrated

by Hannah Punitha on November 11, 2008 at 6:07 PM
 US Chapter of 'Advinus Therapeutics' Inaugrated

Advinus Therapeutics, a TATA group, contract research services and pharmaceutical drug discovery company, based in Bangalore announced that it has started its US operations by incorporating a wholly owned subsidiary, Advinus Therapeutics Inc.

The U.S. Company will be operating out of its office in Research Triangle Park, North Carolina.


In addition the company also announced that it has appointed Dr. Eric Nelson as its Global Head of Business Development, Marketing and Strategy.

Dr. Nelson with over 20 years of corporate and business development experience with both large pharmaceutical and biotechnology companies would be based out of the company's US office and will have the responsibility of managing its operations.

Eric joins Advinus from Tranzyme Pharma where he was Vice President of Business Development and Licensing. Previously he was Assistant Vice President of Global Business Development at Wyeth Pharmaceuticals.

Speaking on the start of US operations, Dr. Rashmi Barbhaiya, the CEO and Managing Director of the company stated, Advinus has a very large and growing client base in the US. In addition we now have multiple drug discovery alliances and collaborations with both Large Pharma and Biotechs based out of the US. One of the main reasons to start the US operations of our company is to build on these relationships and to expand into new ones.

Rajiv Malik, the SVP and Head of Business Operations at Advinus added, Having Eric as our Head of Business Development in the US would help bridge the distance that most US companies feel when working with R and D companies in this part of the world. Now a US based company does not have to wait till the end of business day for them to be able to talk to us.

Source: ANI
Font : A-A+



Latest Drug News

Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

US Chapter of 'Advinus Therapeutics' Inaugrated Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests